Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL everolimus dosing schedule study
NL-OMON41877Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Everolimus pharmacokinetics. Started Jun 2015; status: recruiting.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON41877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41877.